Welcome to our dedicated page for Aptose Bioscienc news (Ticker: APTO), a resource for investors and traders seeking the latest updates and insights on Aptose Bioscienc stock.
Aptose Biosciences Inc. (APTO) generates a steady flow of news as a clinical-stage precision oncology company focused on acute myeloid leukemia (AML) and other myeloid malignancies. Company press releases emphasize the development of its lead oral kinase inhibitor tuspetinib (TUS), particularly in a triple drug frontline regimen with venetoclax (VEN) and azacitidine (AZA) for newly diagnosed AML patients who are ineligible for induction chemotherapy.
On this page, readers can follow Aptose announcements on the TUSCANY Phase 1/2 trial, which evaluates the TUS+VEN+AZA triplet. Recent updates describe dose-escalation decisions, safety reviews, and early clinical outcomes such as complete remissions and measurable residual disease (MRD)-negative responses in patients with challenging mutational profiles, including TP53‑mutated/complex karyotype AML and FLT3‑wildtype AML. These releases also discuss the absence of dose-limiting toxicities at reported dose levels and the maintenance of standard-of-care dosing for venetoclax and azacitidine.
Beyond clinical data, Aptose news items cover corporate and regulatory developments, such as financing arrangements, a reverse share split, a committed equity facility, and at‑the‑market (ATM) programs designed to support ongoing clinical work. The company also reports on collaborations, including a Cooperative Research and Development Agreement with the U.S. National Cancer Institute for tuspetinib in myeloMATCH trials, and licensing and financing relationships with Hanmi Pharmaceutical related to tuspetinib.
Investors and observers can use this news feed to track trial milestones, safety and efficacy updates, capital markets actions, auditor changes, and listing status disclosures. Bookmark this page to monitor how Aptose’s tuspetinib-based programs and related corporate activities evolve over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.